ARTICLE | Company News
PharmAthene, Siga infectious news
January 2, 2012 8:00 AM UTC
The Delaware Court of Chancery denied Siga's motion for reargument, upholding a September judgment that awarded PharmAthene a 50% share of profits from the sale of Siga's ST-246 smallpox antiviral. PharmAthene said it will submit a proposal of final judgment to the court, which will outline a definition of "net profits." Siga said that it intends to appeal the final decision and judgment to the Delaware Supreme Court (see BioCentury, Sept. 26, 2011 & Oct. 24, 2011). ...